Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market

Report Scope

The report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class.

By symptom type, IBS therapeutics include IBS with constipation (IBS-C), IBS with diarrhea (IBS-D) and IBS with mixed symptoms (IBS-M).

By drug class, IBS therapeutics include guanylate cyclase-C agonists, antibiotics, laxatives, antispasmodics and others.

The IBD therapeutics segment is further segmented based on type and drug class.

By type, IBD therapeutics include ulcerative colitis and Crohn’s disease.

By drug class, therapeutics for IBD include interleukin inhibitors, integrin antagonists, TNF inhibitors, JAK (Janus kinases) inhibitors, and others

The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also included.

The scope does not cover alternative therapies for IBS and IBD, such as herbal medicine, dietary supplements and behavioral therapies.

Report Includes

142 data tables and 54 additional tables

Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics

Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030

Estimates of the market’s size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region

Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors

Insights derived from Porter’s Five Forces model, as well as global supply chain analysis

Patent analysis, featuring key granted and published patents

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies

Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc.

Companies Mentioned

ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BIOGEN
BRISTOL-MYERS SQUIBB CO.
GILEAD SCIENCES INC.
IRONWOOD
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
PFIZER INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
UCB S.A.